GlassScriptPhysician profile
Kelli Jo Dumm
NPI 1760461164
$2,530.60
in general payments reported to CMS, 2019-2025
28 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $292 · 2021: $438 · 2022: $405 · 2023: $262 · 2024: $564 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $358.16 | 2020-2025 | Qulipta |
| Pfizer INC. | $191.26 | 2019-2025 | |
| Lilly USA, LLC | $151.35 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $111.31 | 2019-2025 | Trelegy Ellipta, Rotarix, Pediarix |
| Sumitomo Pharma America, INC. | $86.80 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $79.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.91 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $48.35 | 2020-2021 | |
| Allergan, INC. | $48.13 | 2020 | |
| Abbott Laboratories | $47.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.09 | 2022 | |
| Merck Sharp & Dohme LLC | $44.97 | 2019-2020 | |
| Dexcom, INC. | $34.83 | 2023-2024 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.21 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.87 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $30.09 | 2019-2021 | |
| Axsome Therapeutics, INC. | $26.76 | 2025 | Auvelity |
| Philips North America LLC | $24.82 | 2024 | (5044) Mcot |
| Neos Therapeutics, LP | $21.20 | 2020 | |
| Astellas Pharma US INC | $18.02 | 2024 | Veozah |
| Amgen INC. | $15.96 | 2024 | Krystexxa |
| Amarin Pharma, INC. | $15.63 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.83 | 2019 | |
| Aytu Biopharma, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Dumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.